Cargando…

The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition

Sodium–glucose cotransporter 2 inhibitors (SGLT2i) effectively lower plasma glucose (PG) concentration in patients with type 2 diabetes, but studies have suggested that circulating glucagon concentrations and endogenous glucose production (EGP) are increased by SGLT2i, possibly compromising their gl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hædersdal, Sofie, Lund, Asger, Nielsen-Hannerup, Elisabeth, Maagensen, Henrik, van Hall, Gerrit, Holst, Jens J., Knop, Filip K., Vilsbøll, Tina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2020
Materias:	Metabolism
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7679772/ https://www.ncbi.nlm.nih.gov/pubmed/33004472 http://dx.doi.org/10.2337/db20-0369

Ejemplares similares

Glucose-Dependent Insulinotropic Polypeptide: A Bifunctional Glucose-Dependent Regulator of Glucagon and Insulin Secretion in Humans
por: Christensen, Mikkel, et al.
Publicado: (2011)

Unprecedented high insulin secretion in a healthy human subject after intravenous glucagon-like peptide-1: a case report
por: Knop, Filip K, et al.
Publicado: (2014)

A glucose-insulin-glucagon coupled model of the isoglycemic intravenous glucose infusion experiment
por: Subramanian, Vijaya, et al.
Publicado: (2022)

On the role of gallbladder emptying and incretin hormones for nutrient-mediated TSH suppression in patients with type 2 diabetes
por: Sonne, David P, et al.
Publicado: (2014)

The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion—A Review
por: Mathiesen, David S., et al.
Publicado: (2019)

Amylin and Calcitonin: Potential Therapeutic Strategies to Reduce Body Weight and Liver Fat
por: Mathiesen, David S., et al.
Publicado: (2021)

The Glucagonostatic and Insulinotropic Effects of Glucagon-Like Peptide 1 Contribute Equally to Its Glucose-Lowering Action
por: Hare, Kristine J., et al.
Publicado: (2010)

Glucose-Dependent Insulinotropic Polypeptide (GIP) Reduces Bone Resorption in Patients With Type 2 Diabetes
por: Christensen, Mikkel B, et al.
Publicado: (2020)

Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion
por: Wewer Albrechtsen, Nicolai J., et al.
Publicado: (2016)

GIP and GLP-1 Potentiate Sulfonylurea-Induced Insulin Secretion in Hepatocyte Nuclear Factor 1α Mutation Carriers
por: Christensen, Alexander S., et al.
Publicado: (2020)

How glucagon-like peptide 1 receptor agonists work
por: Andreasen, Christine Rode, et al.
Publicado: (2021)

Glimepiride monotherapy versus combination of glimepiride and linagliptin therapy in patients with HNF1A-diabetes: a protocol for a randomised, double-blinded, placebo-controlled trial
por: Sidelmann Christensen, Alexander, et al.
Publicado: (2018)

Effects of glucagon‐like peptide‐1 receptor agonists on cardiovascular risk factors: A narrative review of head‐to‐head comparisons
por: Dalsgaard, Niels B., et al.
Publicado: (2017)

Efficacy and Safety of Glimepiride With or Without Linagliptin Treatment in Patients With HNF1A Diabetes (Maturity-Onset Diabetes of the Young Type 3): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial (GLIMLINA)
por: Christensen, Alexander S., et al.
Publicado: (2020)

The effect of a glucagon-like peptide-1 receptor agonist on glucose tolerance in women with previous gestational diabetes mellitus: protocol for an investigator-initiated, randomised, placebo-controlled, double-blinded, parallel intervention trial
por: Foghsgaard, Signe, et al.
Publicado: (2013)

Protocol for Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetes Cases (The MAG1C trial): a randomised, double-blinded, placebo-controlled trial
por: Johansen, Nicklas Järvelä, et al.
Publicado: (2018)

Glucagon Receptor Signaling and Glucagon Resistance
por: Janah, Lina, et al.
Publicado: (2019)

Glucagon-Like Peptide 2 Inhibits Postprandial Gallbladder Emptying in Man: A Randomized, Double-Blinded, Crossover Study
por: Hansen, Nina L., et al.
Publicado: (2020)

Glucagon Receptor Signaling and Lipid Metabolism
por: Galsgaard, Katrine D., et al.
Publicado: (2019)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

The dietary education trial in carbohydrate counting (DIET-CARB Study): study protocol for a randomised, parallel, open-label, intervention study comparing different approaches to dietary self-management in patients with type 1 diabetes
por: Ewers, Bettina, et al.
Publicado: (2019)

Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes
por: Holst, Jens J., et al.
Publicado: (2011)

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials
por: Vilsbøll, Tina, et al.
Publicado: (2012)

Determining the role of SGLT2 inhibition with Empagliflozin in the development of diabetic retinopathy
por: Matthews, Jennifer, et al.
Publicado: (2022)

Effects of basic carbohydrate counting versus standard outpatient nutritional education (The BCC Study): study protocol for a randomised, parallel open-label, intervention study focusing on HbA1c and glucose variability in patients with type 2 diabetes
por: Ewers, Bettina, et al.
Publicado: (2019)

Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review
por: Hansen, Katrine B, et al.
Publicado: (2010)

Protocol for a randomised, double-blinded, placebo-controlled, double-dummy 6-week clinical trial comparing the treatment effects of the glucagon-like peptide 1 receptor agonist liraglutide versus the bile acid sequestrant colesevelam on bile acid malabsorption
por: Kårhus, Martin Lund, et al.
Publicado: (2021)

Response to Letter to the Editor from McKee and McGill: “Glycemic Control and Variability of Diabetes Secondary to Total Pancreatectomy Assessed by Continuous Glucose Monitoring”
por: Juel, Caroline T B, et al.
Publicado: (2021)

Mechanisms of the Incretin Effect in Subjects with Normal Glucose Tolerance and Patients with Type 2 Diabetes
por: Mari, Andrea, et al.
Publicado: (2013)

No changes in levels of bone formation and resorption markers following a broad-spectrum antibiotic course
por: Mikkelsen, Kristian H., et al.
Publicado: (2018)

Secretion of Glucose-Dependent Insulinotropic Polypeptide in Patients With Type 2 Diabetes: Systematic review and meta-analysis of clinical studies
por: Calanna, Salvatore, et al.
Publicado: (2013)

A 25-Year-Old Woman with Type 2 Diabetes and Liver Disease
por: Junker, Anders Ellekær, et al.
Publicado: (2014)

Circulating Glucagon 1-61 Regulates Blood Glucose by Increasing Insulin Secretion and Hepatic Glucose Production
por: Wewer Albrechtsen, Nicolai J., et al.
Publicado: (2017)

No detectable effect of a type 2 diabetes-associated TCF7L2 genotype on the incretin effect
por: Mathiesen, David S, et al.
Publicado: (2020)

One Year’s Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial
por: Vedtofte, Louise, et al.
Publicado: (2020)

Glucagon Receptor Knockout Prevents Insulin-Deficient Type 1 Diabetes in Mice
por: Lee, Young, et al.
Publicado: (2011)

Hepatic Glucagon Action Is Essential for Exercise-Induced Reversal of Mouse Fatty Liver
por: Berglund, Eric D., et al.
Publicado: (2011)

Hepatic TRAF2 Regulates Glucose Metabolism Through Enhancing Glucagon Responses
por: Chen, Zheng, et al.
Publicado: (2012)

Fgf15 Neurons of the Dorsomedial Hypothalamus Control Glucagon Secretion and Hepatic Gluconeogenesis
por: Picard, Alexandre, et al.
Publicado: (2021)

A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes
por: Andersen, Andreas, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tm3j5v2dkb7dsb5afoj8dnn3lu